Lakefront Biotherapeutics revenue and financials
€26.30Change from previous close: +2.49%Absolute change: +€0.64
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 1,112 | 276 | 240 | 241 |
| Cost of revenue | 29.7 | 34.9 | 0.0 | 0.0 |
| Gross profit | 1,083 | 241 | 240 | 241 |
| Selling, general and administrative | 112 | 96.9 | 94.3 | 103 |
| Research and development | 459 | 335 | 241 | 270 |
| Operating income | 501 | -188 | -88.3 | -131 |
| EBIT | 303 | -2.2 | 7.4 | -61.7 |
| EBITDA | 359 | 43.3 | 51.0 | 3.9 |
| Interest expense | 2.2 | 0.9 | 1.8 | 9.2 |
| Pre-tax income | 301 | -3.1 | 5.6 | -70.8 |
| Income tax | -18.6 | -1.8 | 9.6 | 0.6 |
| Net income | 321 | 74.1 | 212 | -218 |
| Net income to common shareholders | 321 | 74.1 | 212 | -218 |
| Basic EPS | 4.87 | 1.12 | 3.21 | -3.32 |
| Diluted EPS | 4.87 | 1.12 | 3.21 | -3.32 |
| Average shares (basic) | 65.9 | 66.1 | 65.9 | 65.7 |
| Average shares (diluted) | 65.9 | 66.1 | 65.9 | 65.7 |